Resveratrol promotes non-amyloidogenic processing of the amyloid precursor protein (APP) to reduce the level of Aβ in the brain of AD animals, and it reduces microglial and astrocytic activation by inhibiting the activation of c-Jun amino-terminal kinase (JNK) and glycogen synthase kinase 3β (GSK-3β), thus alleviating cognitive dysfunction in animal models of AD [56,57]. This evidence concerns the gene APP and Alzheimer disease.